Fatty Acid Bile Acid Conjugates Inhibit Atherosclerosis in the C57BL/6 Mouse Model
- 1 January 2002
- journal article
- Published by S. Karger AG in Pathobiology
- Vol. 70 (4) , 215-218
- https://doi.org/10.1159/000069332
Abstract
Objective: The aim of the current research was to study whether fatty acid bile acid conjugates (FABACs) have a beneficial effect on atherosclerosis progression and blood lipid levels in mice. Methods: C57BL/6 female mice, fed a high-fat Paigen diet, were administered an oral dose of FABAC or DDH2O daily. Quantification of atherosclerotic fatty-streak lesions at the aortic sinus was performed. Results: The FABAC-treated mice showed a significant reduction in the atherosclerotic lesion areas as compared to the control group (p = 0.019). A significant elevation in total cholesterol levels was observed in both the FABAC and control groups. Higher FABAC levels were measured in the high-density lipoprotein fraction as compared to the very-low-density and low-density lipoprotein fractions. Conclusion: Our findings demonstrate that FABACs, given orally, reduce the development of atherosclerosis in mice fed a high-fat high-cholesterol diet, despite a lack of effect on plasma lipid levels.Keywords
This publication has 6 references indexed in Scilit:
- Dissolution of cholesterol gallstones in mice by the oral administration of a fatty acid bile acid conjugateHepatology, 2002
- Lowering of HDL cholesterol in post-menopausal women by tibolone is not associated with changes in cholesterol efflux capacity or paraoxonase activityAtherosclerosis, 2001
- The Role of High-Density Lipoproteins in Oxidation and InflammationTrends in Cardiovascular Medicine, 2001
- Fatty acid bile acid conjugates (FABACs)---New molecules for the prevention of cholesterol crystallisation in bileGut, 2001
- Increased atherosclerosis in mice reconstituted with apolipoprotein E null macrophagesProceedings of the National Academy of Sciences, 1997
- Effects on coronary artery disease of lipid-lowering diet, or diet plus cholestyramine, in the St Thomas' Atherosclerosis Regression Study (STARS)The Lancet, 1992